The Impact of Somatic and Germline RET Mutations in Medullary Thyroid Cancer
Vivek Subbiah, MD, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies.
Vivek Subbiah, MD, an associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, and executive medical director, Department of Medical Oncology Research at the University of Texas MD Anderson Cancer Center, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies.
Over 60% of patients with metastatic MTC harbor the RET mutations, says Subbiah. In addition, a large proportion of patients also harbor germline MEN1 and MEN2 mutations. The presence of these germline RET mutations account for 20% of all cases of MTC.
RET mutations lead to more aggressive disease, Subbiah explains. The majority of these patients need to be treated with a RET inhibitor. In contrast, in papillary, anaplastic, and differentiation thyroid cancer, the presence of a RET fusion is seen as a driver mechanism.
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
